Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57326Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 鄭永銘(Yung-Ming Jeng) | |
| dc.contributor.author | Tsung-Lin Liu | en |
| dc.contributor.author | 劉宗霖 | zh_TW |
| dc.date.accessioned | 2021-06-16T06:41:47Z | - |
| dc.date.available | 2019-10-09 | |
| dc.date.copyright | 2014-10-09 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-07-29 | |
| dc.identifier.citation | 1. Samartzis D, Nishi N, Cologne J et al. Ionizing radiation exposure and the development of soft-tissue sarcomas in atomic-bomb survivors. J Bone Joint Surg Am 2013; 95: 222-229.
2. Berrington de Gonzalez A, Kutsenko A, Rajaraman P. Sarcoma risk after radiation exposure. Clin Sarcoma Res 2012; 2: 18. 3. Nakanishi H, Tomita Y, Myoui A et al. Mutation of the p53 gene in postradiation sarcoma. Lab Invest 1998; 78: 727-733. 4. Pahwa P, McDuffie HH, Dosman JA et al. Hodgkin lymphoma, multiple myeloma, soft tissue sarcomas, insect repellents, and phenoxyherbicides. J Occup Environ Med 2006; 48: 264-274. 5. Hay A. Phenoxy herbicides, trichlorophenols, and soft-tissue sarcomas. Lancet 1982; 1: 1240. 6. Hoppin JA, Tolbert PE, Herrick RF et al. Occupational chlorophenol exposure and soft tissue sarcoma risk among men aged 30-60 years. Am J Epidemiol 1998; 148: 693-703. 7. Andre S, Schatz O, Bogner JR et al. Detection of antibodies against viral capsid proteins of human herpesvirus 8 in AIDS-associated Kaposi's sarcoma. J Mol Med (Berl) 1997; 75: 145-152. 8. Fletcher JA, Kozakewich HP, Hoffer FA et al. Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. N Engl J Med 1991; 324: 436-442. 9. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology 2006; 48: 13-21. 10. Borden EC, Baker LH, Bell RS et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 2003; 9: 1941-1956. 11. Ladanyi M, Bridge JA. Contribution of molecular genetic data to the classification of sarcomas. Hum Pathol 2000; 31: 532-538. 12. Mertens F, Panagopoulos I, Mandahl N. Genomic characteristics of soft tissue sarcomas. Virchows Arch 2010; 456: 129-139. 13. Bridge JA, Cushman-Vokoun AM. Molecular diagnostics of soft tissue tumors. Arch Pathol Lab Med 2011; 135: 588-601. 14. Delattre O, Zucman J, Plougastel B et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-165. 15. Tanas MR, Goldblum JR. Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. Adv Anat Pathol 2009; 16: 383-391. 16. Galili N, Davis RJ, Fredericks WJ et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 5: 230-235. 17. Davis RJ, D'Cruz CM, Lovell MA et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994; 54: 2869-2872. 18. Crew AJ, Clark J, Fisher C et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. Embo j 1995; 14: 2333-2340. 19. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580. 20. Nishida T, Hirota S, Taniguchi M et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998; 19: 323-324. 21. Lauer S, Gardner JM. Soft tissue sarcomas—New approaches to diagnosis and classification. Current Problems in Cancer 2013; 37: 45-61. 22. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003; 3: 685-694. 23. Perot G, Chibon F, Montero A et al. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol 2010; 177: 2080-2090. 24. Montgomery E, Argani P, Hicks JL et al. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 2004; 164: 1523-1529. 25. Blackburn EH. Telomeres. Trends Biochem Sci 1991; 16: 378-381. 26. Meeker AK, Coffey DS. Telomerase: a promising marker of biological immortality of germ, stem, and cancer cells. A review. Biochemistry (Mosc) 1997; 62: 1323-1331. 27. Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell 2013; 152: 390-393. 28. Nugent CI, Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev 1998; 12: 1073-1085. 29. Weinrich SL, Pruzan R, Ma L et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997; 17: 498-502. 30. Kirkpatrick KL, Mokbel K. The significance of human telomerase reverse transcriptase (hTERT) in cancer. Eur J Surg Oncol 2001; 27: 754-760. 31. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002; 66: 407-425, table of contents. 32. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002; 21: 598-610. 33. Nakayama J, Tahara H, Tahara E et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998; 18: 65-68. 34. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 2001; 269: 1-12. 35. Kyo S, Kanaya T, Takakura M et al. Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer 1999; 80: 60-63. 36. Kirkpatrick KL, Ogunkolade W, Elkak AE et al. hTERT expression in human breast cancer and non-cancerous breast tissue: correlation with tumour stage and c-Myc expression. Breast Cancer Res Treat 2003; 77: 277-284. 37. Bilsland AE, Stevenson K, Atkinson S et al. Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3. Cancer Res 2006; 66: 1363-1370. 38. Deng WG, Jayachandran G, Wu G et al. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells. J Biol Chem 2007; 282: 26460-26470. 39. Yatabe N, Kyo S, Maida Y et al. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 2004; 23: 3708-3715. 40. Xu D, Wang Q, Gruber A et al. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 2000; 19: 5123-5133. 41. Oh S, Song Y, Yim J, Kim TK. The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J Biol Chem 1999; 274: 37473-37478. 42. Nault JC, Mallet M, Pilati C et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013; 4: 2218. 43. Huang FW, Hodis E, Xu MJ et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339: 957-959. 44. Borssen M, Cullman I, Noren-Nystrom U et al. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup. Exp Hematol 2011; 39: 1144-1151. 45. Rachakonda PS, Hosen I, de Verdier PJ et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A 2013; 110: 17426-17431. 46. Horn S, Figl A, Rachakonda PS et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339: 959-961. 47. Patton EE, Harrington L. Cancer: Trouble upstream. Nature 2013; 495: 320-321. 48. Wei GH, Badis G, Berger MF et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. Embo j 2010; 29: 2147-2160. 49. Bryan TM, Englezou A, Gupta J et al. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14: 4240-4248. 50. Park KH, Rha SY, Kim CH et al. Telomerase activity and telomere lengths in various cell lines: changes of telomerase activity can be another method for chemosensitivity evaluation. Int J Oncol 1998; 13: 489-495. 51. Grobelny JV, Godwin AK, Broccoli D. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J Cell Sci 2000; 113 Pt 24: 4577-4585. 52. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010; 11: 319-330. 53. Cesare AJ, Griffith JD. Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol Cell Biol 2004; 24: 9948-9957. 54. Wang RC, Smogorzewska A, de Lange T. Homologous recombination generates T-loop-sized deletions at human telomeres. Cell 2004; 119: 355-368. 55. Nabetani A, Ishikawa F. Unusual telomeric DNAs in human telomerase-negative immortalized cells. Mol Cell Biol 2009; 29: 703-713. 56. Henson JD, Cao Y, Huschtscha LI et al. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol 2009; 27: 1181-1185. 57. Matsuo T, Shimose S, Kubo T et al. Alternative lengthening of telomeres as a prognostic factor in malignant fibrous histiocytomas of bone. Anticancer Res 2010; 30: 4959-4962. 58. Sanders RP, Drissi R, Billups CA et al. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol 2004; 22: 3790-3797. 59. Ulaner GA, Hoffman AR, Otero J et al. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 2004; 41: 155-162. 60. Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-1203. 61. Lovejoy CA, Li W, Reisenweber S et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012; 8: e1002772. 62. Xue Y, Gibbons R, Yan Z et al. The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc Natl Acad Sci U S A 2003; 100: 10635-10640. 63. Picketts DJ, Higgs DR, Bachoo S et al. ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome. Hum Mol Genet 1996; 5: 1899-1907. 64. Gibbons RJ, Suthers GK, Wilkie AO et al. X-linked alpha-thalassemia/mental retardation (ATR-X) syndrome: localization to Xq12-q21.31 by X inactivation and linkage analysis. Am J Hum Genet 1992; 51: 1136-1149. 65. Ritchie K, Seah C, Moulin J et al. Loss of ATRX leads to chromosome cohesion and congression defects. J Cell Biol 2008; 180: 315-324. 66. Goldberg AD, Banaszynski LA, Noh KM et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010; 140: 678-691. 67. Drane P, Ouararhni K, Depaux A et al. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev 2010; 24: 1253-1265. 68. Yao Z, Zhang Q, Li X et al. Death domain-associated protein 6 (Daxx) selectively represses IL-6 transcription through histone deacetylase 1 (HDAC1)-mediated histone deacetylation in macrophages. J Biol Chem 2014; 289: 9372-9379. 69. Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997; 89: 1067-1076. 70. Takahashi Y, Lallemand-Breitenbach V, Zhu J, de The H. PML nuclear bodies and apoptosis. Oncogene 2004; 23: 2819-2824. 71. Salomoni P, Khelifi AF. Daxx: death or survival protein? Trends Cell Biol 2006; 16: 97-104. 72. Michaelson JS, Bader D, Kuo F et al. Loss of Daxx, a promiscuously interacting protein, results in extensive apoptosis in early mouse development. Genes Dev 1999; 13: 1918-1923. 73. Michaelson JS, Leder P. RNAi reveals anti-apoptotic and transcriptionally repressive activities of DAXX. J Cell Sci 2003; 116: 345-352. 74. Chen LY, Chen JD. Daxx silencing sensitizes cells to multiple apoptotic pathways. Mol Cell Biol 2003; 23: 7108-7121. 75. Morozov VM, Massoll NA, Vladimirova OV et al. Regulation of c-met expression by transcription repressor Daxx. Oncogene 2008; 27: 2177-2186. 76. Wethkamp N, Klempnauer KH. Daxx is a transcriptional repressor of CCAAT/enhancer-binding protein beta. J Biol Chem 2009; 284: 28783-28794. 77. Lin DY, Lai MZ, Ann DK, Shih HM. Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential. J Biol Chem 2003; 278: 15958-15965. 78. Chang CC, Lin DY, Fang HI et al. Daxx mediates the small ubiquitin-like modifier-dependent transcriptional repression of Smad4. J Biol Chem 2005; 280: 10164-10173. 79. Lewis PW, Elsaesser SJ, Noh KM et al. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A 2010; 107: 14075-14080. 80. Wong LH, McGhie JD, Sim M et al. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res 2010; 20: 351-360. 81. Griewank KG, Schilling B, Murali R et al. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol 2014; 27: 502-508. 82. Killela PJ, Reitman ZJ, Jiao Y et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013; 110: 6021-6026. 83. Yeager TR, Neumann AA, Englezou A et al. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999; 59: 4175-4179. 84. Heaphy CM, Subhawong AP, Hong SM et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011; 179: 1608-1615. 85. Heaphy CM, de Wilde RF, Jiao Y et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011; 333: 425. 86. Chen SF, Kasajima A, Yazdani S et al. Clinicopathologic significance of immunostaining of alpha-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors. Hum Pathol 2013; 44: 2199-2203. 87. Stratton MR, Moss S, Warren W et al. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 1990; 5: 1297-1301. 88. Ohali A, Avigad S, Naumov I et al. Different telomere maintenance mechanisms in alveolar and embryonal rhabdomyosarcoma. Genes Chromosomes Cancer 2008; 47: 965-970. 89. Costa A, Daidone MG, Daprai L et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 2006; 66: 8918-8924. 90. Henson JD, Hannay JA, McCarthy SW et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005; 11: 217-225. 91. Gocha AR, Nuovo G, Iwenofu OH, Groden J. Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies. Am J Pathol 2013; 182: 41-48. 92. Matsuo T, Shay JW, Wright WE et al. Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas. J Bone Joint Surg Am 2009; 91: 928-937. 93. Venturini L, Daidone MG, Motta R et al. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. Neuro Oncol 2012; 14: 736-744. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57326 | - |
| dc.description.abstract | 從基因分型角度來看，肉瘤可被分為兩大類：一類是簡單染色體組型肉瘤；另一類是複雜色體組型肉瘤。
端粒的縮短為細胞分裂時必然發生的現象，當端粒縮短至一定程度後，細胞即停止分裂或死亡，腫瘤細胞要無限制地生長必須克服此一限制。目前已知克服端粒縮短的機制主要有兩種：一是活化端粒酶；另一則是透過端粒替代性延長（alternative lengthening of telomere, ALT）。在胰臟神經內分泌瘤（pancreatic neuroendocrine tumor, p-NET）中，此端粒替代性延長機制是由ATRX或DAXX失去表現所導致。 我們共收集了195例的肉瘤檢體，其中簡單染色體組型肉瘤共62例，及複雜染色體組型肉瘤133例。透過ATRX、DAXX免疫組織染色及端粒特異性螢光原位雜交，我們發現在複雜染色體組型的軟組織肉瘤中，常帶有ATRX表現量喪失（P = 0.049）及端粒替代性延長（P = 0.004）的現象。所有195例肉瘤中，DAXX並無表現喪失。在58例多形性未分化肉瘤中，共21例為經放射線治療後續發之惡性肉瘤。ATRX表現量喪失（P = 0.007）及端粒替代性延長（P < 0.001）常表現在多形性未分化肉瘤，但經放射線治療後續發之惡性肉瘤並無此現象發生。我們的研究結果顯示，在複雜染色體組型的軟組織肉瘤中，帶有ATRX表現量喪失的腫瘤常伴有表現端粒替代性延長機制，且在多形性未分化肉瘤當中，ATRX表現量喪失及端粒替代性延長是其維持端粒長度的主要機制。 | zh_TW |
| dc.description.abstract | From a genetic perspective, sarcomas tend to fall into two groups: one is sarcomas with simple karyotypes and other one is sarcomas with complex karyotypes.
Telomere shortening is an inevitable phenomenon during cell division. Once telomere has shortened to a critical length, cells undergo replicative senescence. Tumor cells must overcome this limitation to become immortal. There are two major mechanisms for telomere length maintenance; one is the activation of telomerase. The other is the alternative lengthening of telomeres, which in pancreatic neuroendocrine tumor is caused by mutation and loss of expression of either ATRX or DAXX. We collected 195 cases of sarcoma which were composed of 62 type I sarcomas and 133 type II sarcomas. By immunohistochemical stain of ATRX/DAXX and telomere-specific fluorescence in situ hybridization, we found ATRX was frequently loss (P = 0.049) and ALT usually occurred in karyotype-complex sarcomas (P = 0.004). None of the 195 cases lost DAXX expression. Within the 58 cases of undifferentiated pleomorphic sarcoma, 21 cases were post-irradiation sarcoma. Both ATRX loss of expression (P = 0.007) and ALT (P < 0.001) occur in undifferentiated pleomorphic sarcoma but not in post-irradiation sarcoma. Our results indicate that loss of ATRX is associated with ALT phenotype in karyotype-complex sarcoma and ATRX loss and ALT is a major mechanism of telomere preservation in undifferentiated pleomorphic sarcoma. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T06:41:47Z (GMT). No. of bitstreams: 1 ntu-103-R00444008-1.pdf: 6102335 bytes, checksum: 679b08bcd511a67ce4280878c12aa0f0 (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 口試委員審定書 II
謝辭 III 中文摘要 IV Abstract V Contents VII 1.Introduction 1 1.1 Soft tissue sarcoma 1 1.2 Telomere and telomerase 3 1.3 Telomere maintenance 4 1.4 Activation of telomerase 4 1.5 Alternative lengthening of telomere (ALT) 5 1.6 Alpha thalassemia/mental retardation syndrome X-linked (ATRX) 7 1.7 Death domain-associated protein (DAXX) 7 1.8 Aims of this study 9 2. Materials and Methods 10 2.1 Immunohistochemical stain 10 2.2 Fluorescence in situ hybridization 11 2.3 Statistical analysis 12 3.Results 13 3.1 Study cohort 13 3.2 ATRX is frequently loss in some types of sarcoma but DAXX is not 13 3.3 ATRX is frequently loss in undifferentiated pleomorphic sarcoma 14 3.4 Frequent ALT in type II sarcomas 14 3.5 Frequent ALT in undifferentiated pleomorphic sarcoma 14 3.6 Association of ALT and ATRX loss in undifferentiated pleomorphic sarcomas 15 4.Discussion 16 5. Figures and Tables 20 Table 1. The expression of ATRX and DAXX in various sarcomas 20 Table 2. ATRX expression in undifferentiated pleomorphic sarcoma 21 Table 3. Alternative lengthening of telomeres phenotype in different type of sarcoma 22 Figure 1. H&E, DAXX and ATRX immunohistochemical stain in alveolar rhabdomyosarcoma 23 Figure 2. H&E, DAXX and ATRX immunohistochemical stain in dermatofibrosarcoma protuberans (DFSP) 24 Figure 3. DAXX and ATRX immunohistochemical stain in gastrointestinal stromal tumor (GIST) 25 Figure 4. H&E, DAXX and ATRX immunohistochemical stain in primitive neuroectodermal tumor (PNET) 26 Figure 5. H&E, DAXX and ATRX immunohistochemical stain in synovial sarcoma 27 Figure 6. H&E, DAXX and ATRX immunohistochemical stain in botryoid rhabdomyosarcoma 28 Figure 7. H&E, DAXX and ATRX immunohistochemical stain in chondrosarcoma 29 Figure 8. H&E, DAXX and ATRX immunohistochemical stain, and telomere-specific FISH in embryonal rhabdomyosarcoma 30 Figure 9. H&E, DAXX and ATRX immunohistochemical stain in malignant solitary fibrous tumor 32 Figure 10. DAXX and ATRX immunohistochemical stain in malignant peripheral nerve sheath tumor (MPNST) 33 Figure 11. H&E, DAXX and ATRX immunohistochemical stain, and telomere-specific FISH in myxofibrosarcoma 34 Figure 12. H&E, DAXX and ATRX immunohistochemical stain in osteosarcoma 36 Figure 13. H&E, DAXX and ATRX immunohistochemical stain in pleomorphic rhabdomyosarcoma 37 Figure 14. H&E, DAXX and ATRX immunohistochemical stain, and telomere-specific FISH in undifferentiated pleomorphic sarcoma 38 Table 6. Alternative lengthening of telomere phenotype in sarcomas 41 6.Reference 42 | |
| dc.language.iso | en | |
| dc.subject | 端粒維持 | zh_TW |
| dc.subject | 端粒替代性延長 | zh_TW |
| dc.subject | 軟組織肉瘤 | zh_TW |
| dc.subject | ATRX | zh_TW |
| dc.subject | alternative lengthening of telomeres (ALT) | en |
| dc.subject | telomere maintenance | en |
| dc.subject | ATRX | en |
| dc.subject | soft tissue sarcoma | en |
| dc.title | 軟組織肉瘤ATRX表現喪失及端粒替代性延長和腫瘤分類的關係 | zh_TW |
| dc.title | Loss of ATRX expression and alternative lengthening of telomere in soft tissue sarcoma: the relationship with tumor classification | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳彥榮(Yen-Rong Chen),周涵怡(Han-Yi Chou),連晃駿(Huang-Chun Lien) | |
| dc.subject.keyword | 端粒維持,端粒替代性延長,ATRX,軟組織肉瘤, | zh_TW |
| dc.subject.keyword | telomere maintenance,alternative lengthening of telomeres (ALT),ATRX,soft tissue sarcoma, | en |
| dc.relation.page | 48 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-07-29 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 病理學研究所 | zh_TW |
| Appears in Collections: | 病理學科所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| ntu-103-1.pdf Restricted Access | 5.96 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.